GUIDELINES ON UROLITHIASIS

(Update February 2012)

C. Türk (chairman), T. Knoll (vice-chairman), A. Petrik, K. Sarica, C. Seitz, M. Straub

Epidemiology

Between 1,200 and 1,400 per 100,000 will develop urinary stones each year with a male/female ratio of 3:1. A number of known factors of influence to the development of stones are discussed in more detail in the extended version of the Urolithiasis guidelines.

Classification of stones

Correct classification of stones is important since it will impact treatment decisions and outcome.

Urinary stones can be classified according to the following aspects: stone size, stone location, X-ray characteristics of stone, aetiology of stone formation, stone composition (mineralogy), and risk group for recurrent stone formation (Tables 1-3).

Table 1: X-ray characteristics			
Radiopaque	Poor radiopaque	Radiolucent	
Calcium oxalate dihydrate	Magnesium ammonium phos- phate	Uric acid	
Calcium oxalate monohydrate	Apatite	Ammonium urate	
Calcium phos- phates	Cystine	Xanthine	
		2,8-dihydroxyade- nine	
		'Drug-stones'	

Table 2: Stones classified according to their aetiology			
Non infec-	Infection	Genetic	Drug stones
tion stones	stones	stones	
Calcium	Magnesium	Cystine	e.g. Indinavir
oxalates	ammonium		(see extended
	phosphate		document)
Calcium	Apatite	Xanthine	
phosphates			
Uric acid	Ammonium	2,8-dihy-	
	urate	droxyadenine	

Table 3: Stones classified by their composition		
Chemical composition	Mineral	
Calcium oxalate monohydrate	whewellite	
Calcium-oxalate-dihydrate	wheddelite	
Uric acid dihydrate	uricite	
Ammonium urate		

Magnesium ammonium phosphate	struvite
Carbonate apatite (phosphate)	dahllite
Calcium hydrogenphosphate	brushite
Cystine	
Xanthine	
2,8-dihydroxyadenine	
'Drug stones'	

Risk groups for stone formation

The risk status of a stone former is of particular interest as it defines both probability of recurrence or (re)growth of stones and is imperative for pharmacological treatment.

General factors

Early onset of urolithiasis in life (especially children and teenagers)

Familial stone formation

Brushite containing stones (calcium hydrogen phosphate; CaHPO4.2H2O)

Uric acid and urate containing stones

Infection stones

Solitary kidney (The solitary kidney itself does not present an increased risk of stone formation, but prevention of stone recurrence is more important)

Diseases associated with stone formation

Hyperparathyroidism

Nephrocalcinosis

Gastrointestinal diseases or disorders (e.g. jejuno-ileal bypass, intestinal resection, Crohn's disease, malabsorptive conditions, enteric hyperoxaluaria after urinary diversion)

Sarcoidosis

Genetically determined stone formation

Cystinuria (type A, B, AB)

Primary hyperoxaluria (PH)

Renal tubular acidosis (RTA) type I

2,8-dihydroxyadenine

Xanthinuria

Lesh-Nyhan-Syndrome

Cystic fibrosis

Drugs associated with stone formation (see Chapter 11 extended text)

Anatomical abnormalities associated with stone formation

Medullary sponge kidney (tubular ectasia)

UPI obstruction

Calyceal diverticulum, calyceal cyst

Ureteral stricture

Vesico-uretero-renal reflux

Horseshoe kidney

Ureterocele

DIAGNOSIS Diagnostic imaging

Standard evaluation of a patient includes taking a detailed medical history and physical examination. The clinical diagnosis should be supported by an appropriate imaging procedure.

Recommendation	LE	GR
With fever or solitary kidney, and when diagnosis is doubtful, immediate imaging is indicated.	4	A*

^{*}Upgraded following panel consensus.

If available, ultrasonography, should be used as the primary diagnostic imaging tool although pain relief, or any other emergency measures should not be delayed by imaging assessments. KUB should not be performed if NCCT is considered; however, it is helpful in differentiating between radiolucent and radiopaque stones and for comparison during follow-up.

Evaluation of patients with acute flank pain

Non-contrast enhanced computed tomography (NCCT) has become the standard for diagnosis of acute flank pain since it has higher sensitivity and specificity than IVU.

Recommendation	LE	GR
NCCT should be used to confirm stone diag-	1a	A
nosis in patients with acute flank pain, because		
it is superior to IVU		

Indinavir stones are the only stones not detectable on NCCT.

Recommendation	LE	GR
A renal contrast study (enhanced CT or IVU)	3	A*
is indicated when planning treatment for renal		
stones.		

^{*}Upgraded following panel consensus.

Biochemical work-up

Each emergency patient with urolithiasis needs a succinct biochemical work-up of urine and blood besides the imaging studies. At that point no difference is made between highand low-risk patients.

Recommendations: Basic analysis emergency stone patient		
Urine	GR	
Urinary sediment/dipstick test out of spot urine sam-	A*	
ple for: red cells / white cells / nitrite / urine pH level		
by approximation		
Urine culture or microscopy	A	
Blood		
Serum blood sample creatinine / uric acid / ionized	A*	
calcium / sodium / potassium / CRP		
Blood cell count	A*	
If intervention is likely or planned: Coagulation test	A*	
(PTT and INR)		

^{*}Upgraded following panel consensus.

Examination of sodium, potassium, CRP, and blood coagulation time can be omitted in the non-emergency stone patient.

Patients at high risk for stone recurrences should undergo a more specific analytical programme (*see* section MET below).

Analysis of stone composition should be performed in all first-time stone formers (GR: A). It should be repeated in case of:

Recurrence under pharmacological prevention

- Early recurrence after interventional therapy with complete stone clearance
- Late recurrence after a prolonged stone-free period (GR: B)

The preferred analytical procedures are:

- X-ray diffraction (XRD)
- Infrared spectroscopy (IRS)

Wet chemistry is generally deemed to be obsolete.

Acute treatment of a patient with renal colic

Pain relief is the first therapeutic step in patients with an acute stone episode.

LE	GR
1b	A
4	С
1b	A
	1b

GFR = glomerular filtration rate; NSAID = non-steroidal antiinflammatory drug.

*Caution: Diclofenac sodium affects GFR in patients with reduced renal function, but not in patients with normal renal function (LE: 2a). ** (see extended document section 5.3)

If pain relief cannot be achieved by medical means, drainage, using stenting or percutaneous nephrostomy, or stone removal, should be carried out.

Management of sepsis in the obstructed kidney

The obstructed, infected kidney is a urological emergency.

Recommendations	LE	GR
For sepsis with obstructing stones, the collect-	1b	A
ing system should be urgently decompressed,		
using either percutaneous drainage or ureteral		
stenting.		
Definitive treatment of the stone should be	1b	A
delayed until sepsis is resolved.		

In exceptional cases, with severe sepsis and/or the formation of abscesses, an emergency nephrectomy may become necessary.

Further Measures - Recommendations	GR
Collect urine for antibiogram following decompres-	A*
sion.	
Start antibiotics immediately thereafter (+ intensive	
care if necessary).	
Revisit antibiotic treatment regimen following anti-	
biogram findings.	

^{*} Upgraded based on panel consensus.

Stone relief

When deciding between active stone removal and conservative treatment using MET, it is important to consider all the individual circumstances of a patient that may affect treatment decisions.

Observation of ureteral stones

Recommendations	LE	GR
In patients with newly diagnosed ureteral	la	A
stones < 10 mm, and if active stone removal is		
not indicated, observation with periodic evalu-		
ation is optional initial treatment.		
Such patients may be offered appropriate medi-		
cal therapy to facilitate stone passage during		
the observation period*.		

^{*}see also Section MET

Observation of kidney stones

It is still debatable whether kidney stones should be treated, or whether annual follow-up is sufficient for asymptomatic caliceal stones that have remained stable for 6 months.

Recommendations	GR
Kidney stones should be treated in case of growth,	A
formation of de novo obstruction, associated infec-	
tion, and acute and/or chronic pain.	
Comorbidity and patient preference need to be taken	С
into consideration when making treatment decisions.	
If kidney stones are not treated, periodic evaluation	
is needed.	

^{*} Upgraded following panel consensus.

Medical expulsive therapy (MET)

For patients with ureteral stones that are expected to pass spontaneously, NSAID tablets or suppositories (i.e. diclofenac sodium, 100-150 mg/day, over 3-10 days) may help to reduce inflammation and the risk of recurrent pain.

Alpha-blocking agents, given on a daily basis, reduce recurrent colic (LE: 1a). Tamsulosin, has been the most commonly used alpha blocker in studies.

Recommendations for MET	LE	GR
For MET, alpha-blockers or nifedipine are recommended.		A
Patients should be counselled about the attendant risks of MET, including associated drug side effects, and should be informed that it is administered as 'off-label' use.		A*
Patients, who elect for an attempt at spontaneous passage or MET, should have well-controlled pain, no clinical evidence of sepsis, and adequate renal functional reserve.		A
Patients should be followed to monitor stone position and to assess for hydronephrosis.	4	A*
MET in children cannot be recommended due to the limited data in this specific population.	4	С

^{*}Upgraded following panel consensus.

Statements	LE
MET has an expulsive effect also on proximal ureteral	1b
stones.	

After SWL for ureteral or renal stones, MET seems to expedite and increase stone-free rates, reducing additional analgesic requirements.	1a
Based on studies with a limited number of patients, no recommendation for the use of corticosteroids in combination with alpha-blockers in MET can be made	1b

Chemolytic dissolution of stones

Oral or percutaneous irrigation chemolysis of stones can be a useful first-line therapy or an adjunct to SWL, PNL, URS, or open surgery to support elimination of residual fragments. However, its use as first-line therapy may take weeks to be effective.

Percutaneous irrigation chemolysis

Recommendations	GR
In percutaneous chemolysis, at least two nephrostomy catheters should be used to allow irrigation of the renal collecting system, while preventing chemolytic fluid draining into the bladder and reducing the risk	A
of increased intrarenal pressure*. Pressure- and flow-controlled systems should be used if available.	

^{*} Alternatively, one nephrostomy catheter with a II stent and bladder catheter can serve as a through-flow system preventing high pressure.

Methods of percutaneous irrigation chemolysis

Stone composition	Irrigation solution	Comments
Struvite Carbon apatite	10% Hemiacidrin, pH 3.5-4 Suby's G	Combination with SWL for staghorn stones Risk of cardiac arrest due to hypermagnesaemia
Brushite	Hemiacidrin Suby's G	Can be considered for residual fragments
Cystine	Trihydroxymethylaminomethan (THAM; 0.3 or 0.6 mol/L), pH 8.5-9.0	Takes signifi- cantly longer time than for uric acid stones
	N-acetylcysteine (200 mg/L)	Used for elimination of residual fragments
Uric acid	Trihydroxymethylaminomethan (THAM; 0.3 or 0.6 mol/L), pH 8.5-9.0	Oral chemolysis is the preferred option

Oral Chemolysis

Oral chemolitholysis is efficient for uric acid calculi only. The urine pH should be adjusted to between 7.0 and 7.2.

Recommendations	
The dosage of alkalising medication must be modified	A
by the patient according to the urine pH, which is a	
direct consequence of the alkalising medication.	
Dipstick monitoring of urine pH by the patient is	
required at regular intervals during the day. Morning	
urine must be included.	
The physician should clearly inform the patient of	
the significance of compliance.	

SWL

The success rate for SWL will depend on the efficacy of the lithotripter and on:

- size, location (ureteral, pelvic or calyceal), and composition (hardness) of the stones;
- patient's habitus;
- · performance of SWL.

Contraindications of SWL

Contraindications to the use of SWL are few, but include:

- pregnancy;
- · bleeding diatheses;
- uncontrolled urinary tract infections;
- severe skeletal malformations and severe obesity, which prevent targeting of the stone;
- · arterial aneurism in the vicinity of the stone;
- anatomical obstruction distal of the stone.

Stenting prior to SWL

Kidney stones

A JJ stent reduces the risk of renal colic and obstruction, but does not reduce formation of steinstrasse or infective complications.

Recommendation - stenting & SWL	LE	GR
Routine stenting is not recommended as part of	1b	A
SWL treatment of ureteral stones.		

Best clinical practice (best performance)

Pacemaker

Patients with a pacemaker can be treated with SWL, provided that appropriate technical precautions are taken; patients with implanted cardioverter defibrillators must be managed with special care (firing mode temporarily reprogrammed during SWL treatment). However, this might not be necessary with new-generation lithotripters.

Recommendation - Shock wave rate	LE	GR
The optimal shock wave frequency is 1.0	1a	A
(to 1.5) Hz.		

Number of shock waves, energy setting and repeat treatment sessions

- The number of shock waves that can be delivered at each session depends on the type of lithotripter and shockwave power.
- Starting SWL on a lower enegy setting with step-wise power (and SWL sequence) ramping prevents renal injury.

 Clinical experience has shown that repeat sessions are feasible (within 1 day for ureteral stones).

Procedural control

Results of treatment are operator dependent. Careful imaging control of localisation will contribute to outcome quality.

Pain control

Careful control of pain during treatment is necessary to limit pain-induced movements and excessive respiratory excursions.

Antibiotic prophylaxis

No standard prophylaxis prior to SWL is recommended.

Recommendation	LE	GR
In case of infected stones or bacteriuria, antibi-	4	С
otics should be given prior to SWL.		

Medical expulsive therapy (MET) after SWL

MET after SWL for ureteral or renal stones can expedite expulsion and increase stone-free rates, as well as reduce additional analgesic requirements.

Percutaneous nephrolitholapaxy (PNL)

Recommendation	GR
Ultrasonic, ballistic and Ho:YAG devices are recom-	A*
mended for intracorporeal lithotripsy using rigid	
nephroscopes.	
When using flexible instruments, the Ho:YAG laser is	
currently the most effective device available.	

^{*} Upgraded following panel consensus.

Best clinical practice

Contraindications:

- · all contraindications for general anaesthesia apply;
- · untreated UTI;
- · atypical bowel interposition;
- · tumour in the presumptive access tract area;
- · potential malignant kidney tumour;
- pregnancy.

Pre-operative recommendation - imaging	GR
Preprocedural imaging, including contrast medium	A*
where possible or retrograde study when starting the	
procedure, is mandatory to assess stone comprehen-	
siveness, view the anatomy of the collecting system,	
and ensure safe access to the kidney stone.	

^{*} Upgraded based on panel consensus.

Positioning of the patient: prone or supine?

Traditionally, the patient is positioned prone for PNL, supine position is also possible, showing advantages in shorter operating time, the possibility of simultaneous ret-

rograde transurethral manipulation, and easier anaesthesia. Disadvantages are limited manoeuvrability of instruments and the need of appropriate equipment.

Nephrostomy and stents after PNL

Recommendation	LE	GR
In uncomplicated cases, tubeless (without	1b	A
nephrostomy tube) or totally tubeless (without		
nephrostomy tube and without ureteral stent)		
PNL procedures provide a safe alternative.		

Ureterorenoscopy (URS)

(including retrograde access to renal collecting system)

Best clinical practice in URS

Before the procedure, the following information should be sought and actions taken (LE: 4):

- Patient history;
- physical examination (i.e. to detect anatomical and congenital abnormalities);
- · thrombocyte aggregation inhibitors/anticoagulation (anti-platelet drugs) treatment should be discontinued. However, URS can be performed in patients with bleeding disorders, with only a moderate increase in complications;
- imaging.

Recommendation	GR
Short-term antibiotic prophylaxis should be admin-	A*
istered.	

Contraindications

Apart from general considerations, e.g. with general anaesthesia, URS can be performed in all patients without any specific contraindications.

Access to the upper urinary tract

Most interventions are performed under general anaesthesia, although local or spinal anaesthesia are possible. Intravenous sedation is possible for distal stones, especially in women. Antegrade URS is an option for large, impacted proximal ureteral calculi.

Safety aspects

Fluoroscopic equipment must be available in the operating room. If ureteral access is not possible, the insertion of a JJ stent followed by URS after a delay of 7-14 days offers an appropriate alternative to dilatation.

Recommendation	GR
Placement of a safety wire is recommended.	A*

^{*}Upgraded following panel consensus.

Ureteral access sheaths

Hydrophilic-coated ureteral access sheaths (UAS), can be inserted via a guide wire, with the tip placed in the proximal ureter. Ureteral access sheaths allow easy multiple access to the upper urinary tract and therefore significantly facilitate URS. The use of UAS improves vision by establishing a continuous outflow, decrease intrarenal pressure and potentially reduce operating time.

Stone extraction

The aim of endourological intervention is complete stone removal (especially in ureteric stones). 'Smash and go' strategies might have a higher risk of stone regrowth and postoperative complications.

Recommendation	LE	GR
Stone extraction using a basket without endo- scopic visualisation of the stone (blind basket- ing) should not be performed.	4	A*
Nitinol baskets preserve the tip deflection of flexible ureterorenoscopes, and the tipless design reduces the risk of mucosa injury. Nitinol baskets are most suitable for use in flexible URS.	3	В
Ho:YAG laser lithotripsy is the preferred method when carrying out (flexible) URS.		В

^{*}Upgraded following panel consensus.

Stenting before and after URS

Pre-stenting facilitates ureteroscopic management of stones, improves the stone-free rate, and reduces complications. Following URS, stents should be inserted in patients who are at increased risk of complications.

Recommendation	LE	GR
Stenting is optional before and after uncompli-	1a	A
cated URS.		

Open surgery

Most stones should be approached primarily with PNL, URS, SWL, or a combination of these techniques. Open surgery may be a valid primary treatment option in selected cases.

Indications for open surgery:

- · Complex stone burden
- · Treatment failure of SWL and/or PNL, or URS
- Intrarenal anatomical abnormalities: infundibular stenosis, stone in the calyceal diverticulum (particularly in an anterior calyx), obstruction of the ureteropelvic junction, stricture if endourologic procedures have failed or are not promising
- · Morbid obesity
- Skeletal deformity, contractures and fixed deformities of hips and legs
- · Comorbidity
- Concomitant open surgery
- Non-functioning lower pole (partial nephrectomy), nonfunctioning kidney (nephrectomy)
- Patient choice following failed minimally invasive procedures; the patient may prefer a single procedure and avoid the risk of needing more than one PNL procedure
- Stone in an ectopic kidney where percutaneous access and SWL may be difficult or impossible
- For the paediatric population, the same considerations apply as for adults.

Laparoscopic surgery

Laparoscopic urological surgery is increasingly replacing open surgery.

Indications for laparoscopic kidney-stone surgery include:

- complex stone burden;
- · failed previous SWL and/or endourological procedures;
- · anatomical abnormalities;
- · morbid obesity;
- · nephrectomy in case of non-functioning kidney.

Indications for laparoscopic ureteral stone surgery include:

- · large, impacted stones;
- · multiple ureteral stones;
- · in cases of concurrent conditions requiring surgery;
- when other non-invasive or low-invasive procedures have failed.

If indicated, for upper ureteral calculi, laparoscopic urolithomy has the highest stone-free rate compared to URS and SWL (LE: 1a).

Laparoscopic ureterolithotomy should be considered when other non-invasive or low-invasive procedures have failed.

Recommendations	LE	GR
Laparoscopic or open surgical stone removal may be considered in rare cases where SWL, URS, and percutaneous URS fail or are unlikely	3	С
to be successful. When expertise is available, laparoscopic surgery should be the preferred option before proceeding to open surgery. An exception is complex renal stone burden and/or stone location.	3	С
For Ureterolithotomy, laparoscopy is recommended for large impact stones or when endoscopic lithotripsy or SWL have failed.	2	В

Indication for active stone removal and selection of procedure

Ureter:

- stones with a low likelihood of spontaneous passage;
- persistent pain despite adequate pain medication;
- persistent obstruction;
- renal insufficiency (renal failure, bilateral obstruction, single kidney).

Kidney:

- stone growth;
- stones in high-risk patients for stone formation;
- obstruction caused by stones;
- · infection;
- symptomatic stones (e.g. pain, haematuria);
- stones > 15 mm;
- stones < 15 mm if observation is not the option of choice;
- patient preference (medical and social situation);
- > 2-3 years persistent stones.

The suspected stone composition might influence the choice of treatment modality.

Recommendations	GR
For asymptomatic caliceal stones in general, active	С
surveillance with an annual follow-up of symp-	
toms and stone status (KUB, ultrasonography [US],	
NCCT) is an option for 2–3 years, whereas interven-	
tion should be considered after this period provided	
patients are adequately informed.	
Observation might be associated with a greater risk of	
necessitating more invasive procedures.	

STONE REMOVAL

Recommendations	GR
Urine culture or urinary microscopy is mandatory	A*
before any treatment is planned.	
Urinary infection should be treated when stone	A
removal is planned.	
Anticoagulation therapy including salicylates should	В
be stopped before stone removal, in particular if SWL	
is planned.	
If intervention for stone removal is essential and sali-	
cylate therapy should not be interrupted, retrograde	
URS is the preferred treatment of choice.	

^{*}Upgraded based on panel consensus.


Radiolucent uric acid stones, but not sodium urate or ammonium urate stones, can be dissolved by oral chemolysis. Determination is done by urinary pH.

Recommendation	GR
Careful monitoring of radiolucent stones during/after	A
therapy is imperative.	

^{*} Upgraded based on panel consensus.

Selection of procedure for active removal of renal stones

Figure 1: Treatment algorithm for renal calculi within the renal pelvis or upper and middle calices




^{*} Flexible URS is used less as first-line therapy for renal stones > 1.5 cm.

^{**} The ranking of the recommendations reflects a panel majority vote.

^{***} see Table 19 extended document

Figure 2: Treatment algorithm for renal calculi in the inferior calyx



Selection of procedure for active stone removal of ureteral stones (GR: A*)

	First choice	Second choice	
Proximal ureter < 10 mm	SWL	URS	
Proximal ureter > 10 mm	URS (retrograde or antegrade)		
	or SWL		
Distal ureter < 10 mm	URS or SWL		
Distal ureter > 10 mm	URS	SWL	

^{*}Upgraded following panel consensus.

Recommendation	GR
Percutaneous antegrade removal of ureteral stones is an alternative when SWL is not indicated or has	A
failed, and when the upper urinary tract is not amenable to retrograde URS.	
Patients should be informed that URS is associated with a better chance of achieving stone-free status with a single procedure, but has higher complication	A
rates.	

Steinstrasse

Steinstrasse occurs in 4% to 7% of cases after SWL, the major factor in steinstrasse formation is stone size.

Recommendations		GR
Medical expulsion therapy increases the stone	1b	A
expulsion rate of steinstrasse.		
PCN is indicated for steinstrasse associated		С
with UTI/fever.		
SWL is indicated for steinstrasse when large		С
stone fragments are present.		
Ureteroscopy is indicated for symptomatic		С
steinstrasse and treatment failure.		

Residual stones

Recommendations	LE	GR
Identification of biochemical risk factors and appropriate stone prevention is particularly indicated in patients with residual fragments or stones.	1b	A
Patients with residual fragments or stones should be followed up regularly to monitor disease course.	4	С
After SWL and URS, MET is recommended using an alpha-blocker to improve fragment clearance and reduce the probability of residual stones.	la	A
For well-disintegrated stone material residing in the lower calix, inversion therapy during high diuresis and mechanical percussion facilitate stone clearance.	la	В

The indication for active stone removal and selection of the procedure is based on the same criteria as for primary stone treatment and also includes repeat SWL.

Management of urinary stones and related problems during pregnancy

Recommendations (GR: A*)

US is the method of choice for practical and safe evaluation of pregnant women.

In symptomatic patients with suspicion of ureteral stones during pregnancy, limited IVU, MRU, or isotope renography is a possible diagnostic method.

Following correct diagnosis, conservative management should be the first-line treatment for all non-complicated cases of urolithiasis in pregnancy (except those that have clinical indications for intervention).

If intervention becomes necessary, placement of an internal stent, percutaneous nephrostomy, or ureteroscopy are treatment options.

Regular follow-up until final stone removal is necessary due to higher encrustation of stents during pregnancy.

Management of stone problems in children

Spontaneous passage of a stone and of fragments after SWL is more likely to occur in children than in adults (LE: 4). For paediatric patients, the indications for SWL and PNL are similar to those in adults, however they pass fragments more easily. Children with renal stones with a diameter up to 20 mm (~300 mm2) are ideal candidates for SWL.

Recommendation	GR
Ultrasound evaluation is the first choice for imaging	A*
in children and should include the kidney, the filled	
bladder and adjoining portions of the ureter.	

^{*}Upgraded from B following panel consensus.

^{*} Upgraded following panel consensus.

Stones in exceptional situations

Caliceal diverticulum stones	SWL, PNL (if possible) or RIRS (retrograde intrarenal surgery via flexible ureter- oscopy). Can also be removed using laparoscopic retroperitoneal surgery. Patients may become asymp- tomatic due to stone disin-
	tegration (SWL) whilst well-disintegrated stone material remains in the original position due to narrow caliceal neck.
Horseshoe kidneys	Can be treated in line with the stone treatment options described above.
	Passage of fragments after SWL might be poor.
Stones in pelvic kidneys	SWL, RIRS or laparoscopic surgery
	For obese patients, the options are SWL, PNL, RIRS or open surgery

Patients with obstruction of	When the outflow abnor-
the ureteropelvic junction	mality has to be corrected,
	stones can be removed
	with either percutaneous
	endopyelotomy or open
	reconstructive surgery.
	URS together endopyelo-
	thomy with Ho:YAG.
	Incision with an Acucise bal-
	loon catheter might be con-
	sidered, provided the stones
	can be prevented from fall-
	ing into the pelvo-ureteral
	incision.
Stones in transplanted kid-	Use of PNL is recommended,
neys	however SWL or (flexible)
-	ureteroscopy are valuable
	alternatives.
Stones formed in urinary	Individual management nec-
division	essary.
	For smaller stones SWL is
	effective.
	PNL and antegrade flexible
	URS are frequently used
	endourological procedures.
Stones formed in a continent	Present a varied and often
reservoir	difficult problem.
	Each stone problem must be
	considered and treated indi-
	vidually.

Stones in patients with neurogenic bladder disorder	For stone removal all methods apply based on individual situation.
	Careful patient follow-up and effective precentive strategies are important.

General considerations for recurrence prevention (all stone patients)

- Drinking advice (2.5 3L/day, neutral pH);
- · Balanced diet:
- · Lifestyle advice.

High-risk patients: stone-specific metabolic work-up and pharmacological recurrence prevention

Pharmacological stone prevention is based on a reliable stone analysis and the laboratory analysis of blood and urine including two consecutive 24-hour urine samples.

Pharmacological treatment of calcium oxalate stones

(Hyperparathyreoidism excluded by blood examination)

Risk factor	Suggested treatment	LE	GR
Hypercalciuria	Thiazide + potassium	la	A
	citrate		
Hyperoxaluria	Oxalate restriction	2b	A
Hypocitraturia	Potassium citrate	1b	A
Enteric hyperoxaluria	Potassium citrate	3-4	С
	Calcium supplement	2	В
	Oxalate absorption	3	В

Small urine volume	Increased fluid intake	1b	A
Distal renal tubular	Potassium citrate	2b	В
acidosis			
Primary hyperoxaluria	Pyridoxine	3	В

Pharmacological treatment of calcium phosphate stones

Risk factor	Rationale	Medication
Hypercalciuria	Calcium	Hydrochlorothiazide, ini-
	excretion	tially 25 mg/day, increas-
	> 8 mmol/day	ing up to 50 mg/day
Inadequate	pH constantly	L-Methionine, 200-500
urine pH	> 6.2	mg 3 times daily, with
		the aim of reducing urine
		pH to 5.8-6.2
Urinary tract	Eradication of	Antibiotics
infection	urea-splitting	
	bacteria	

Hyperparathyroidism

Elevated levels of ionized calcium in serum (or total calcium and albumin) require assessment of intact parathyroid hormone (PTH) to confirm or exclude suspected hyperparathyroidism (HPT). Primary HTP can only be cured by surgery.

Pharmacological treatment of uric acid and ammonium urate stones

Risk factor	Rationale for pharmacological therapy	Medication
Inadequate urine pH	Urine pH constantly ≤ 6.0; 'acidic arrest' in uric acid stones	Alkaline citrate OR Sodium bicarbonate Prevention: targeted urine pH 6.2-6.8 Chemolitholysis: targeted urine pH 7.0-7.2
	Urine pH con- stantly > 6.5 in ammonium urate stones	Adequate antibiotics in case of UTI L-Methionine, 200-500 mg 3 times daily; targeted urine pH 5.8-6.2
Hyperuricosuria	Uric acid excretion > 4.0 mmol/day	Allopurinol, 100 mg/day (LE: 3; GR: B)
	Hyperuricosuria and hyperuricemia > 380 µmol	Allopurinol, 100-300 mg/day, depending on kid- ney function

Struvite and infection stones

Therapeutic measure recommendations	LE	GR
Surgical removal of the stone material as com-		
pletely as possible		
Short-term antibiotic course	3	В
Long-term antibiotic course	3	В
Urinary acidification: ammonium chloride;		В
1 g, 2 - 3 x daily		
Urinary acidification: methionine;	3	В
200-500 mg, 1 - 3 x daily		
Urease inhibition	1b	A

Pharmacological treatment of cystine stones

Risk factor	Rationale for pharmacological therapy	Medication
Cystinuria	Cystine excretion > 3.0-3.5 mmol/day	Tiopronin, 250 mg/ day initially, up to a maximum dose of 2 g/day NB: TACHYPHY- LAXIS IS POSSIBLE (LE: 3; GR: B)
Inadequate urine pH	Improvement of cystine solubility Urine pH optimum 7.5-8.5	Alkaline Citrate or Sodium Bicarbonate Dosage is according to urine pH (LE: 3, GR: B)

2,8-dihydroyadenine stones and xanthine stones

Both stone types are rare. In principle, diagnosis and specific prevention is similar to that of uric acid stones.

Investigating a patient with stones of unknown composition

Investigation	Rationale for investigation
Medical history	- Stone history (former stone events, fam-
	ily history)
	- Dietary habits
	- Medication chart
Diagnostic	- Ultrasound in case of a suspected stone
imaging	- NCCT
	(Determination of the Houndsfield unit
	provides information about the possible
	stone composition)
Blood analysis	- Creatinine
	- Calcium (ionized calcium or total cal-
	cium + albumin)
	- Uric acid
Urinalysis	- Urine pH profile (measurement after
	each voiding, minimum 4 times a day)
	- Dipstick test: leucocytes, erythrocytes,
	nitrite, protein, urine pH, specific
	weight
	- Urine culture
	- Microscopy of urinary sediment
	(morning urine)

This short booklet text is based on the more comprehensive EAU guidelines (ISBN 978-90-79754-83-0) available to all members of the European Association of Urology at their website, http://www.uroweb.org.